Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease.
Albert Selva O'CallaghanF Romero-BuenoE Trallero-AraguásA Gil-VilaJ C Ruiz-RodríguezO Sánchez-PernauteI Pinal-FernándezPublished in: Current treatment options in rheumatology (2021)
Combined immunosuppressive treatment should be considered the first-line therapy for patients with anti-MDA5 rapidly progressive interstitial lung disease. Aggressive rescue therapies may be useful in refractory patients.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- multiple sclerosis
- end stage renal disease
- chronic kidney disease
- breast cancer cells
- newly diagnosed
- ejection fraction
- prognostic factors
- cell death
- peritoneal dialysis
- combination therapy
- signaling pathway
- patient reported outcomes